-
Ebb & Flow Regulatory milestones Arena Pharmaceuticals Inc. (NASDAQ:ARNA) fell $0.77 to $7.63 on Friday's news it is withdrawing an MAA from EMA for obesity drug Belviq lorcaserin to gain more feedback on the …
Published on 5/6/2013
-
Ebb & Flow Panoramic view Natera Inc. raised the fifth biggest venture round for a diagnostic company since the start of 2010, as investors are betting the company's Panorama Prenatal Aneuploidy Test will beat out …
Published on 5/6/2013
-
Ebb & Flow Sufficiently graft-ifying Opsona Therapeutics Ltd. took the rare step of turning down money in last week's series C round, as the immunology company capped the financing at €33 million ($43 million) to …
Published on 5/6/2013
-
Ebb & Flow Tecfidera upside? Investors liked what they heard about Biogen Idec Inc. (NASDAQ:BIIB) last week, sending the company's valuation up $2.4 billion by Friday's close. On Monday, the stock rose $11.93 to $…
Published on 4/29/2013
-
Ebb & Flow Banker tracks Ian Crosbie left Jefferies, where he was a managing director in the European healthcare team. Venture tracks Tim Kilgallon joined Polaris Partners' West Coast office as CEO-in-residence. …
Published on 4/29/2013
-
Ebb & Flow Plenty supply; shrinking demand Table: Earnings on deck Figure: Money Raised in 2013 Table: EPS watch Despite a gloomy quarterly report from PricewaterhouseCoopers and the National Venture Capital …
Published on 4/29/2013
-
Ebb & Flow Drawing 10 of a kind The deal between Avalon Ventures and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) to launch up to 10 early stage companies offers the VC a potential return of more than 10x its investment …
Published on 4/29/2013
-
Plenty supply; shrinking demand Money Raised in 2013 Last week, the biotech industry raised $309 million, bringing to $7.3 billion the total raised year-to-date. In 2012, a total of $36.3 billion was raised, …
Published on 4/29/2013
-
Plenty supply; shrinking demand Earnings on deck At least 23 biotechs and pharmas are slated to report earnings next week. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN)…
Published on 4/29/2013
-
Plenty supply; shrinking demand EPS watch At least 21 biotechs and pharmas reported earnings last week. While big biotechs Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) and Biogen Idec Inc. (NASDAQ:BIIB) added $3.8 …
Published on 4/29/2013
-
Ebb & Flow Regulatory milestones Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) gained $0.09 to $3.29 on Friday after EMA's CHMP backed an MAA for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). …
Published on 4/29/2013
-
Ebb & Flow Convincing converts At least one bondholder is unhappy with last week's plan to split Theravance Inc. (NASDAQ:THRX) into two publicly traded companies. One company - Theravance Biopharma - will be …
Published on 4/29/2013
-
Ebb & Flow Alleviating lesions Morgenthaler believes it has finally found a good entry point into wound healing via Scioderm LLC's $16 million series A round. The proceeds will fund a therapy to treat chronic wounds…
Published on 4/29/2013
-
Ebb & Flow Legal tracks Wendy Goldstein joined Cooley as a partner in its healthcare and life sciences regulatory practice. She was a partner at Epstein Becker & Green. Genevieve Michaux joined Hunton & Williams as…
Published on 4/22/2013
-
Vertex's vertical leap Money Raised in 2013 Last week, the biotech industry raised $228 million, bringing to $6.9 billion the total raised year-to-date. In 2012, a total of $36.3 billion was raised, including $19.9 …
Published on 4/22/2013
-
Vertex's vertical leap Earnings on deck At least 17 biotechs and pharmas are slated to report earnings this week. Four big biotechs - Alexion Pharmaceuticals Inc. (NASDAQ:ALXN), Amgen Inc. (NASDAQ:AMGN), Biogen Idec…
Published on 4/22/2013
-
Vertex's vertical leap EPS watch At least five biotechs and pharmas reported earnings last week. Actelion Ltd. (SIX:ATLN) added more than $230 million to its market value after reporting 1Q13 revenues and EPS that …
Published on 4/22/2013
-
Ebb & Flow Remodeling the model The Thiel Foundation's Breakout Labs program has emerged from its pilot year of awards with modified grant terms intended to create a revolving funding model. The foundation, …
Published on 4/22/2013
-
Ebb & Flow Lucier's long position Life Technologies Corp. (NASDAQ:LIFE) Chairman and CEO Greg Lucier went on a buying spree after taking the helm at predecessor Invitrogen Corp. in 2003. The strategy appears to have…
Published on 4/22/2013
-
Ebb & Flow Regulatory milestones BTG plc (LSE:BTG) was off 12.30p to 344.50p last week after Germany's Institute for Quality and Efficiency in Healthcare (IQWiG) said Zytiga abiraterone from Johnson & Johnson (NYSE:…
Published on 4/22/2013
-
Ebb & Flow Dutch dance Following the results of Elan Corp. plc's $1 billion Dutch auction share buyback last Thursday, Royalty Pharma hopes remaining Elan shareholders will accept an $11.25 per share takeout bid …
Published on 4/22/2013
-
The audiophiles Inner ear pipeline At least 13 compounds are in development for inner ear disorders, including hearing loss, Meniere's disease, tinnitis and vertigo. The most advanced is neramexane to treat tinnitis…
Published on 4/22/2013
-
Sofinnova Partners and Sofinnova Ventures think scientific advances and unmet need in inner ear disorders are making audiology an investable space, with Auris among the leaders in the race.
Published on 4/22/2013
-
Ebb & Flow Vertex's vertical leap Table: Earnings on deck Figure: Money Raised in 2013 Table: EPS watch Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) leapt $32.73 (62%) to $85.60 on Friday after positive Phase II …
Published on 4/22/2013
-
Ebb & Flow Banker tracks Stuart Smartt joined NXT Capital as a managing director and head of healthcare for the firm's corporate finance group. Smartt was a director of the healthcare group at CIT Group. PE tracks…
Published on 4/15/2013